# Services built for teenagers and young adults, and what the national evaluation found

Source: https://onco.cc/technologies/rejuv-ayac-services/  
OnCo record `rejuv-ayac-services` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

England built specialist units for 13 to 24 year olds and then evaluated them nationally, which almost no health system does. The results were mixed enough that young people were asked to interpret them, and they pointed out that three years of follow-up was too short and that the study had defined specialist care by how many admissions a person had rather than how long they spent there.

## Summary

The case for age-specific services is straightforward: a seventeen-year-old on a children's ward or an elderly medical ward is in the wrong place, is unlikely to meet anyone their age, and has needs around education, independence, sexuality and fertility that neither ward is set up for. In the United Kingdom, Teenage Cancer Trust has funded and run specialist units inside NHS hospitals since 1990, with specialist nurses and youth support coordinators, campaigning for age-appropriate care for 13 to 24 year olds. NICE quality standard QS55 covers ages 0 to 24 and is supported by both Teenage Cancer Trust and Teenagers and Young Adults with Cancer, and NICE's 2005 service guideline requires that care be appropriate for the child's or young person's age.

Then England did something unusual and evaluated it. BRIGHTLIGHT was "the first national evaluation of teenage and young adult (TYA) cancer services in England", covering young people aged 13 to 24 at diagnosis, comprising six interlinked studies, with young people involved in design, troubleshooting and dissemination. Its conclusions diverged in ways the professionals could not explain, so the researchers took the results back to the BRIGHTLIGHT Young Advisory Panel for interpretation. The panel made points the researchers had not: that three years of follow-up "was not long enough"; that specialist care had been defined "using number of admissions rather than duration of hospitalisation"; that the higher healthcare costs observed in those receiving care in more than one hospital "could be due to duplication of tests/scans"; and that the results did not convey the importance of the diagnostic experience, which also carried costs to young people and families. This is an unusually honest piece of health services research and it is the reason this record is graded moderate rather than strong: the services are plainly better for the people in them, and the trial-grade evidence that they change outcomes is not there.

What happened next. A policy lab brought eighteen professionals and five young people together to reconcile the evidence with NHS England's service specification for adolescent and young adult cancer, which had been drafted before the BRIGHTLIGHT results were available. It produced eight national and six local recommendations, prioritised into three: launching the service specification with clear communication, harnessing the ideas of young people, and evaluating patient outcomes and experiences through a national dashboard of network performance.

What a young person should expect to be offered. Treatment in or linked to an age-appropriate unit, a key worker, a fertility discussion before treatment starts, educational and employment support, psychological support, and an end-of-treatment summary and care plan with agreed follow-up, which is a NICE quality statement and can be asked for by name.

What comes back, and when: not a physiological question. What these services restore is the ordinary business of being that age during treatment, and the evidence that they do so is largely the testimony of the people who used them, which this record treats as evidence rather than anecdote while saying what kind it is.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; paediatric; late-effects; evidence:moderate
- Principle: Age-appropriate services aim at the non-biological determinants of outcome in this group: trial enrolment, adherence, psychological wellbeing, education and fertility decisions. Because those determinants act slowly and through many paths, a three-year observational evaluation is poorly powered to detect their effect, which is the most likely explanation for the divergence between the measured results and the experience reported by the people receiving the care.
- Strengths: A national evaluation exists at all, which is rare for a service model; Young people were involved in interpreting the results and found what the analysts missed; A clear list of what a young person should be offered, anchored in a NICE quality statement
- Limitations: The national evaluation's results were mixed and the follow-up was short; Specialist care was defined by number of admissions rather than time in specialist care; No randomised evidence that age-specific units change survival

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Teenage_Cancer_Trust
- Evaluation of specialist cancer services for teenagers and young adults in England: interpreting BRIGHTLIGHT study results through the lens of young people with cancer (Res Involv Engagem 2025): https://doi.org/10.1186/s40900-025-00739-7
- When research evidence and healthcare policy collide: synergising results and policy into BRIGHTLIGHT guidance to improve coordinated care for adolescents and young adults with cancer (Healthcare 2025): https://doi.org/10.3390/healthcare13151821
- NICE quality standard QS55: Cancer services for children and young people (2014): https://www.nice.org.uk/guidance/qs55
- NICE cancer service guideline CSG7: Improving outcomes in children and young people with cancer (2005): https://www.nice.org.uk/guidance/csg7
- Cancer Research UK: young people's cancers statistics: https://www.cancerresearchuk.org/health-professional/cancer-statistics/teenagers-and-young-adults-cancers

## Connected records

- institutions: [Teenage Cancer Trust](https://onco.cc/institutions/teenage-cancer-trust/)
- ideas: [A survivorship passport app for adolescent and young adult survivors](https://onco.cc/ideas/idea-acc-aya-survivorship-passport/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/), [Testicular germ cell tumours](https://onco.cc/cancers/testicular/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Adolescents and young adults: a group with its own cancers, its own gap and its own needs](https://onco.cc/technologies/rejuv-ayac-distinct-group/), [Education, work and the years that were interrupted](https://onco.cc/technologies/rejuv-ayac-education-and-work/), [How long it takes to diagnose cancer in a young person, and what the evidence actually says](https://onco.cc/technologies/rejuv-ayac-diagnostic-delay/), [Long-term follow-up in the United Kingdom: what a survivor is actually offered](https://onco.cc/technologies/rejuv-paed-uk-long-term-follow-up/), [Oncofertility and fertility preservation](https://onco.cc/technologies/fertility-preservation/), [The handover from children's to adult services, where follow-up falls away](https://onco.cc/technologies/rejuv-paed-transition-to-adult-care/), [Who gets told about fertility before treatment, and who does not](https://onco.cc/technologies/rejuv-access-fertility-preservation/), [Who misses out on recovery care, measured](https://onco.cc/technologies/rejuv-access-who-misses-out/)
- terms: [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Quality of life](https://onco.cc/terms/quality-of-life/)
- bottlenecks: [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Patients lack understanding, navigation and agency](https://onco.cc/bottlenecks/b-patient-voice/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-ayac-services.json